國家衛生研究院 NHRI:Item 3990099045/8160
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 856860      Online Users : 944
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/8160


    Title: Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma
    Authors: Tsai, HJ;Lin, SF;Chen, CC;Chen, TY;Su, WC;Hwang, WL;Lin, JC;Chiou, TJ;Kao, WY;Chiu, CF;Chang, YF;Chang, JS;Chang, MC;Su, IJ
    Contributors: National Institute of Cancer Research;Division of Biostatistics and Bioinformatics;Division of Infectious Diseases
    Abstract: PURPOSE: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of front-line concurrent chemo-radiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). PATIENTS AND METHODS: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included 2 cycles of the DEP regimen (dexamethasone, etoposide plus cisplatin) every 4 weeks with concurrent 5,040 cGy radiation in 28 fractions for 5 weeks. Patients without disease progression after CCRT were subjected to 2 cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna and cisplatin every 4 weeks. The primary endpoint was tumor response rate and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). RESULTS: Thirty-three patients received CCRT and 29 patients received 2 cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-year and 5-year progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%). CONCLUSION: Front-line CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.
    Date: 2015-02
    Relation: European Journal of Haematology. 2015 Feb;94(2):130-137.
    Link to: http://dx.doi.org/10.1111/ejh.12405
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0902-4441&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000350099700007
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84922846170
    Appears in Collections:[Jeffrey Shu-Ming] Periodical Articles
    [Hui-Jen Tsai] Periodical Articles
    [Chu-Chih Chen] Periodical Articles
    [Ih-Jen Su(2002-2015)] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB24957163.pdf147KbAdobe PDF618View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback